Search - tctmd.com

Displaying 241 - 260 of 5631

Sort: Relevancy | Date

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

Black Adults Face CV Mortality Beyond Their Predicted Risk

Caitlin E. Cox

April 18, 2025

News Daily News

AHA Statement Zeroes In On Sleep Health

L.A. McKeown

April 17, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Daily News

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

L.A. McKeown

April 14, 2025

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News EHRA 2025

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

Todd Neale

April 09, 2025

News Conference News EHRA 2025

Post-TAVI Pacemaker Tied to Poorer Long-term Outcomes

Todd Neale

April 08, 2025

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Features

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Yael L. Maxwell

March 27, 2025

Advertisement

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

April 2025 Dispatch for the CV Team

Black Adults Face CV Mortality Beyond Their Predicted Risk

AHA Statement Zeroes In On Sleep Health

Cardiotoxicity Rare With Common GI Chemotherapy

High BMI Before Pregnancy Tied to Greater CVD Risk Later in Life

Weekend Warriors Also See Mortality Benefits With Exercise

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge

Post-TAVI Pacemaker Tied to Poorer Long-term Outcomes

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s in a Name: Is It Time to Choose Between TAVI and TAVR?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content